Overview

A Study to Assess the Pharmacokinetic Profile, the Safety, and the Tolerability of ME1100 Inhalation Solution in Patients With Mechanically Ventilated Bacterial Pneumonia

Status:
Completed

Trial end date:
2017-03-22

Target enrollment:

Participant gender:

Summary

This study is a randomized, open-label phase I study. The primary objective of this study is to assess the pharmacokinetic (PK) profile of ME1100 in subjects with mechanically ventilated bacterial pneumonia (MVBP). The secondary objective of this study is to assess the safety and tolerability of ME1100 for the treatment of subjects with MVBP to assess the safety and tolerability of ME1100.

Phase:

Phase 1

Details

Lead Sponsor:

Meiji Seika Pharma Co., Ltd.

Treatments:

Arbekacin
Dibekacin
Habekacin
Pharmaceutical Solutions